These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25851791)

  • 1. Pharmacology and controlled release of hirudin for cardiovascular disorders.
    Kim DD; Horbett TA; Takeno MM; Ratner BD
    Cardiovasc Pathol; 1996; 5(6):337-49. PubMed ID: 25851791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular drug highlight: hirudin.
    Cheng-Lai A
    Heart Dis; 1999; 1(1):41-9. PubMed ID: 11720603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
    Fareed J; Walenga JM; Iyer L; Hoppensteadt D; Pifarre R
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):135-47. PubMed ID: 1772981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin.
    Monreal M; Costa J; Salva P
    Drugs Aging; 1996 Mar; 8(3):171-82. PubMed ID: 8720743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current developments in antithrombotic therapy: the role of antithrombin agents.
    Breddin HK
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 3():1-8. PubMed ID: 12811005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of the anticoagulant hirudin: its biotechnological production and clinical practice.
    Sohn JH; Kang HA; Rao KJ; Kim CH; Choi ES; Chung BH; Rhee SK
    Appl Microbiol Biotechnol; 2001 Dec; 57(5-6):606-13. PubMed ID: 11778867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress in the controlled release systems of hirudin].
    Li T; Wan C; Li Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 1998 Dec; 15(4):419-23. PubMed ID: 12552793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hirudin as alternative anticoagulant--a historical review.
    Markwardt F
    Semin Thromb Hemost; 2002 Oct; 28(5):405-14. PubMed ID: 12420235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
    Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
    Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.
    Lancet; 1999 Feb; 353(9151):429-38. PubMed ID: 9989712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hirudin: clinical potential of a thrombin inhibitor.
    Johnson PH
    Annu Rev Med; 1994; 45():165-77. PubMed ID: 8198374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis.
    Harvey RP; Degryse E; Stefani L; Schamber F; Cazenave JP; Courtney M; Tolstoshev P; Lecocq JP
    Proc Natl Acad Sci U S A; 1986 Feb; 83(4):1084-8. PubMed ID: 3513162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
    Yusuf S
    Am J Cardiol; 1999 Sep; 84(5A):20M-25M. PubMed ID: 10505539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hirudin in the treatment of arterial and venous thrombotic diseases: a new perspective.
    Büller HR
    Z Kardiol; 1993; 82 Suppl 2():81-2. PubMed ID: 8328213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The functional domain of hirudin, a thrombin-specific inhibitor.
    Chang JY
    FEBS Lett; 1983 Dec; 164(2):307-13. PubMed ID: 6418572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of recombinant hirudin.
    Nowak G
    Semin Thromb Hemost; 2002 Oct; 28(5):415-24. PubMed ID: 12420236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hirudin and hirudin fragments].
    Deschamps A; Samama M
    Ann Cardiol Angeiol (Paris); 1992 Oct; 41(8):A49-53. PubMed ID: 1298182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty.
    Meyer BJ; Fernández-Ortiz A; Mailhac A; Falk E; Badimon L; Michael AD; Chesebro JH; Fuster V; Badimon JJ
    Circulation; 1994 Nov; 90(5):2474-80. PubMed ID: 7955205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
    Imura Y; Stassen JM; Collen D
    J Pharmacol Exp Ther; 1992 Jun; 261(3):895-8. PubMed ID: 1602394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.